Tag: U.S. Biopharma Imports

Over the past decade, U.S. biopharmaceutical imports have surged, crossing $202 billion in 2023 — doubling in just ten years. Despite America’s powerhouse pharmaceutical sector, the country now runs a $101 billion trade deficit in biopharma, as it increasingly relies on imported raw materials, active pharmaceutical ingredients (APIs), and finished drugs, particularly from China, India,…